Sentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary use Kiora will receive a royalty on net sales of products covered by licensed ...
Salt Lake City, Utah--(Newsfile Corp. - June 27, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") received approval to initiate a first-in-human clinical trial for KIO-301 ...
According to an SEC filing, TOI will pay Kiora an up-front payment of $16 million, and Kiora is eligible to receive milestone payments totaling up to approximately $285 million, upon and subject to ...
Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine. The publication adds clinical detail to a program ...
If the option is exercised, Kiora will receive an additional mid-single digit million up-front payment, development, regulatory, and commercial milestones, plus tiered royalties on sales "Like ...
Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended ...
Please provide your email address to receive an email when new articles are posted on . Théa Open Innovation will receive development and commercialization rights to KIO-301. KIO-301 demonstrated ...
Encinitas, California--(Newsfile Corp. - July 5, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its wholly owned subsidiaries have received, in aggregate, $1.2 million related to ...
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in ...
Kiora Pharmaceuticals Reports Second Quarter 2025 Results Company Advances Pipeline With Two Active Phase 2 Clinical Trials For Retinal Diseases. Encinitas, California-- (Newsfile Corp. - August 8, ...
Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results